JP Morgan: Immunogen, Onyx, BioMarin, Gilead pipeline updates
This article was originally published in Scrip
Executive Summary
If one thing was notably missing during the first day of the 31st Annual JP Morgan Healthcare Conference on 7 January in San Francisco, it was major announcements regarding key clinical trial outcomes or large company acquisitions.